Philippe Sauvage serves as Chief Financial Officer at Nuvation Bio Inc. (Class A), a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. With more than 25 years of experience in the biopharmaceutical sector, Sauvage oversees all financial operations, including strategic planning, investor relations, capital allocation, and risk management. Since joining in 2021, he has been instrumental in guiding the company's financial strategy amid key milestones, such as clinical trial advancements and partnerships, positioning Nuvation Bio for sustainable growth in oncology. Prior to Nuvation Bio, Sauvage was CFO at argenx from 2018 to 2021, where he spearheaded the company's successful Nasdaq IPO, multiple follow-on financings raising over $1 billion, and global expansion efforts that fueled rapid revenue growth. Before argenx, he held senior roles at Shire Pharmaceuticals, including Vice President of Finance for EMEA and Global Head of Commercial Finance, optimizing financial performance across international markets and supporting major acquisitions. Earlier, at Novartis, he advanced through progressively senior finance and controlling positions, honing his expertise in budgeting, forecasting, and operational efficiency. A graduate of INSEAD with an MBA and holder of a Master's degree in Economics from the University of Paris Dauphine, Sauvage's track record of navigating complex financial landscapes in biotech has earned him recognition as a leader in scaling innovative companies from development to commercialization.